Sign in Subscribe
Cancer research

Efficacy and Safety of Online Adaptive Magnetic Resonance-guided Fractionated Stereotactic Radiotherapy in Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Researchers at Sun Yat-sen University in Guangdong, People's Republic of China, have published a study evaluating the efficacy and safety of online adaptive magnetic resonance-guided fractionated stereotactic radiotherapy (FSRT) in patients with brain metastases from non-small cell lung cancer (NSCLC). The study found promising results, with a 1-year intracranial progression-free survival (IPFS) rate of 78.7% and a median IPFS of 21.9 months. The treatment also showed minimal side effects, with only one case of grade 1 radiation necrosis.

Key Takeaways:

  • The study aimed to evaluate the efficacy and safety of online adaptive MR-guided FSRT in patients with brain metastases from NSCLC.
  • The study included 55 patients with a median age of 58 years and 82% presenting with adenocarcinoma.
  • The 1-year IPFS rate was 78.7% (95% CI, 68.2%-90.7%), with a median IPFS of 21.9 months (95% CI, 13.8-30.1 months).
  • The 1-year progression-free survival (PFS) rate was 63.5% (95% CI: 51.8%-78.2%), and overall survival (OS) was 82.4% (95% CI: 72.6%-93.6%).
  • The objective response rate (ORR) reached 78% (95% CI: 65.0%-88.2%).
  • Treatment-related toxicity was minimal, with only one case (2%) of grade 1 radiation necrosis.
  • Quality of life improved steadily, with the Global Health Status score increasing from 65.67 +/- 16.97 to 79.33 +/- 8.79 at 6 months post-FSRT (p < 0.001).

Statistics:

  • 55 patients were enrolled in the study with a median age of 58 years.
  • 18/55 (33%) patients were female.
  • 45/55 (82%) patients presented with adenocarcinoma.
  • 1-year IPFS rate was 78.7% (95% CI, 68.2%-90.7%).
  • 1-year PFS rate was 63.5% (95% CI: 51.8%-78.2%).
  • OS rate was 82.4% (95% CI: 72.6%-93.6%).
  • ORR reached 78% (95% CI: 65.0%-88.2%).
  • Treatment-related toxicity was minimal, with only one case (2%) of grade 1 radiation necrosis.

Sources:

  • Efficacy and Safety of Online Adaptive Magnetic Resonance-guided Fractionated Stereotactic Radiotherapy for Brain Metastases In Non-small Cell Lung Cancer (Gasto-1075): a Single-arm, Phase 2 Trial. eClinicalMedicine, 2025;82:103189.
  • Sun Yat-sen University, Guangdong Prov Clin Res Ctr Canc, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Cancer Center, Guangzhou, Guangdong, People's Republic of China.
  • Immunotherapy Weekly. May 14, 2025; p 1541.
  • NewsRx LLC.

Read more